• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Wednesday's Intraday Session

    11/22/23 12:31:08 PM ET
    $ATHE
    $ATPC
    $BIVI
    $HSCS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medical/Nursing Services
    Health Care
    Get the next $ATHE alert in real time by email

    Gainers

    • PaxMedica (NASDAQ:PXMD) shares rose 33.6% to $1.07 during Wednesday's regular session. The market value of their outstanding shares is at $1.1 million.
    • Impel Pharmaceuticals (NASDAQ:IMPL) shares increased by 32.68% to $0.42. The company's market cap stands at $10.1 million.
    • BioVie (NASDAQ:BIVI) stock rose 29.03% to $5.6. The company's market cap stands at $211.3 million.
    • Seelos Therapeutics (NASDAQ:SEEL) shares moved upwards by 22.61% to $0.16. The market value of their outstanding shares is at $25.7 million.
    • Heart Test Laboratories (NASDAQ:HSCS) shares rose 22.38% to $0.24. The company's market cap stands at $5.3 million.
    • Agape ATP (NASDAQ:ATPC) stock rose 20.8% to $1.15. The market value of their outstanding shares is at $88.6 million.

    Losers

    • Entrada Therapeutics (NASDAQ:TRDA) stock fell 30.2% to $11.64 during Wednesday's regular session. The market value of their outstanding shares is at $388.4 million.
    • Alterity Therapeutics (NASDAQ:ATHE) stock declined by 29.63% to $1.68. The market value of their outstanding shares is at $6.8 million.
    • Mira Pharmaceuticals (NASDAQ:MIRA) shares fell 23.98% to $2.96. The company's market cap stands at $43.8 million.
    • Alaunos Therapeutics (NASDAQ:TCRT) shares decreased by 21.67% to $0.06. The market value of their outstanding shares is at $14.0 million.
    • Inspire Veterinary (NASDAQ:IVP) stock decreased by 20.25% to $0.56. The market value of their outstanding shares is at $4.9 million.
    • UpHealth (NYSE:UPH) shares declined by 17.91% to $0.65. The market value of their outstanding shares is at $11.1 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $ATHE alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ATHE
    $ATPC
    $BIVI
    $HSCS

    CompanyDatePrice TargetRatingAnalyst
    Entrada Therapeutics Inc.
    $TRDA
    2/11/2026$20.00Buy
    Guggenheim
    Entrada Therapeutics Inc.
    $TRDA
    1/28/2026$21.00Outperform
    Oppenheimer
    Alterity Therapeutics Limited
    $ATHE
    2/3/2025Speculative Buy → Hold
    The Benchmark Company
    Alterity Therapeutics Limited
    $ATHE
    12/12/2024$8.00Buy
    Maxim Group
    Entrada Therapeutics Inc.
    $TRDA
    12/6/2024$29.00Buy
    ROTH MKM
    Entrada Therapeutics Inc.
    $TRDA
    1/5/2024$22.00Outperform
    Oppenheimer
    Entrada Therapeutics Inc.
    $TRDA
    4/3/2023$25.00Buy
    H.C. Wainwright
    Alaunos Therapeutics Inc.
    $TCRT
    10/4/2022$3.00Overweight
    Wells Fargo
    More analyst ratings

    $ATHE
    $ATPC
    $BIVI
    $HSCS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    HeartSciences' MyoVista Insights™ Receives Epic Toolbox Designation for ECG Management System Category

    Southlake, TX , March 25, 2026 (GLOBE NEWSWIRE) -- HeartSciences Inc.  (NASDAQ:HSCS, HSCSW)) ("HeartSciences" or the "Company"), a healthcare information technology ("HIT") company focused on advancing electrocardiography ("ECG" or "EKG") through the integration of artificial intelligence ("AI"), today announced that its MyoVista Insights™ platform has received Epic Toolbox designation for the ECG Management System category. MyoVista Insights is a cloud-native ECG management and analysis platform designed to enhance workflow efficiency and support clinical decision-making. The platform supports integration with hospital information systems and electronic health records ("EHRs"), including

    3/25/26 8:30:00 AM ET
    $HSCS
    Industrial Specialties
    Health Care

    HeartSciences to Present at Investor Summit Group Virtual Conference and Host Virtual One on One Investor Meetings

    Southlake, TX, March 24, 2026 (GLOBE NEWSWIRE) -- HeartSciences Inc.  (NASDAQ:HSCS, HSCSW)) ("HeartSciences" or the "Company"), a healthcare information technology ("HIT") company focused on advancing electrocardiography ("ECG" or "EKG") through the integration of artificial intelligence ("AI"), will present at Investor Summit Group Virtual Conference, March 25, 2026 at 12:30 pm ET. Hosted by Investor Summit Group, a premier platform connecting microcap companies with leading investors, the event provides a highly efficient forum for emerging growth companies to engage directly with institutional investors, family offices, and high-net-worth individuals. Event Details: Conference: Inves

    3/24/26 11:18:08 AM ET
    $HSCS
    Industrial Specialties
    Health Care

    HeartSciences Reports Fiscal Third Quarter 2026 Financial Results and Provides Business Update

    Southlake, Texas, March 16, 2026 (GLOBE NEWSWIRE) -- HeartSciences Inc.  (NASDAQ:HSCS, HSCSW)) ("HeartSciences" or the "Company"), a healthcare information technology ("HIT") company focused on advancing electrocardiography ("ECG" or "EKG") through the integration of artificial intelligence ("AI"), today reported financial results for its fiscal third quarter ended January 31, 2026 ("FQ3 2026") and provided a business update. Third Quarter and Recent Highlights During the third quarter and subsequent period, the Company continued advancing the commercialization of its MyoVista Insights™ healthcare IT platform and submitted its MyoVista® wavECG™ device to the U.S. Food and Drug Administra

    3/16/26 4:15:00 PM ET
    $HSCS
    Industrial Specialties
    Health Care

    $ATHE
    $ATPC
    $BIVI
    $HSCS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Guggenheim initiated coverage on Entrada Therapeutics with a new price target

    Guggenheim initiated coverage of Entrada Therapeutics with a rating of Buy and set a new price target of $20.00

    2/11/26 7:51:55 AM ET
    $TRDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Oppenheimer initiated coverage on Entrada Therapeutics with a new price target

    Oppenheimer initiated coverage of Entrada Therapeutics with a rating of Outperform and set a new price target of $21.00

    1/28/26 7:58:46 AM ET
    $TRDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Alterity Therapeutics downgraded by The Benchmark Company

    The Benchmark Company downgraded Alterity Therapeutics from Speculative Buy to Hold

    2/3/25 7:02:17 AM ET
    $ATHE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ATHE
    $ATPC
    $BIVI
    $HSCS
    SEC Filings

    View All

    SEC Form 6-K filed by Alterity Therapeutics Limited

    6-K - ALTERITY THERAPEUTICS LTD (0001131343) (Filer)

    3/26/26 11:26:55 AM ET
    $ATHE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SCHEDULE 13D filed by BioVie Inc.

    SCHEDULE 13D - BIOVIE INC. (0001580149) (Subject)

    3/25/26 5:00:26 PM ET
    $BIVI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    MIRA Pharmaceuticals Inc. filed SEC Form 8-K: Other Events

    8-K - MIRA PHARMACEUTICALS, INC. (0001904286) (Filer)

    3/23/26 9:00:36 AM ET
    $MIRA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ATHE
    $ATPC
    $BIVI
    $HSCS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Entrada Therapeutics Inc.

    4 - Entrada Therapeutics, Inc. (0001689375) (Issuer)

    3/11/26 4:35:13 PM ET
    $TRDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Entrada Therapeutics Inc.

    4 - Entrada Therapeutics, Inc. (0001689375) (Issuer)

    3/11/26 4:34:08 PM ET
    $TRDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Financial Officer Wentworth Kory James sold $97,892 worth of shares (7,988 units at $12.25), decreasing direct ownership by 5% to 137,987 units (SEC Form 4)

    4 - Entrada Therapeutics, Inc. (0001689375) (Issuer)

    3/6/26 4:36:45 PM ET
    $TRDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ATHE
    $ATPC
    $BIVI
    $HSCS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Baker Bros. Advisors Lp bought $261,846 worth of shares (28,867 units at $9.07) (SEC Form 4)

    4 - Entrada Therapeutics, Inc. (0001689375) (Issuer)

    11/24/25 4:09:49 PM ET
    $TRDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Large owner Baker Bros. Advisors Lp bought $1,352,587 worth of shares (178,044 units at $7.60) (SEC Form 4)

    4 - Entrada Therapeutics, Inc. (0001689375) (Issuer)

    11/12/25 5:34:18 PM ET
    $TRDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    President & CEO Do Cuong V bought 5,000 shares (SEC Form 4)

    4 - BIOVIE INC. (0001580149) (Issuer)

    8/13/25 4:05:17 PM ET
    $BIVI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ATHE
    $ATPC
    $BIVI
    $HSCS
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for TRUDHESA issued to IMPEL NEUROPHARMA INC

    Submission status for IMPEL NEUROPHARMA INC's drug TRUDHESA (ORIG-1) with active ingredient DIHYDROERGOTAMINE MESYLATE has changed to 'Approval' on 09/02/2021. Application Category: NDA, Application Number: 213436, Application Classification: Type 5 - New Formulation or New Manufacturer

    9/13/21 2:21:35 PM ET
    $IMPL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for DIHYDROERGOTAMINE MESYLATE issued to IMPEL NEUROPHARMA INC

    Submission status for IMPEL NEUROPHARMA INC's drug DIHYDROERGOTAMINE MESYLATE (ORIG-1) with active ingredient DIHYDROERGOTAMINE MESYLATE has changed to 'Approval' on 09/02/2021. Application Category: NDA, Application Number: 213436, Application Classification: Type 5 - New Formulation or New Manufacturer

    9/7/21 1:04:43 PM ET
    $IMPL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ATHE
    $ATPC
    $BIVI
    $HSCS
    Leadership Updates

    Live Leadership Updates

    View All

    Alterity Therapeutics Appoints Daniel O. Claassen, M.D., M.S., as Chief Medical Advisor

    MELBOURNE, Australia and SAN FRANCISCO, March 04, 2026 (GLOBE NEWSWIRE) -- Alterity Therapeutics ((ASX: ATH, NASDAQ:ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that Daniel O. Claassen, M.D., M.S., was appointed Chief Medical Advisor and will begin his role in March 2026. As a tenured professor, Dr. Claassen will also retain his academic appointment at Vanderbilt University Medical Center. Dr. Claassen is a board-certified neurologist and internationally recognized expert in neurodegenerative diseases, with more than two decades of clinical and translational research in mov

    3/4/26 7:25:00 AM ET
    $ATHE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Alterity Therapeutics: Appendix 4C – Q2 FY26 Quarterly Cash Flow Report & Corporate Update

    − Phase 2 Data Strengthened, Strong Cash Position, and Phase 3 Planning Well Advanced − Highlights Phase 2 data for ATH434 in Multiple System Atrophy (MSA) strengthened by additional analyses and multiple international scientific presentations during the quarter.Regulatory planning activities advancing toward a pivotal Phase 3 program, including preparation for FDA End-Of-Phase-2 meeting in mid-2026.Ongoing partnering and strategic discussions with pharmaceutical companies and corporate advisers to explore non-dilutive pathways to fund Phase 3 development.Board and executive leadership strengthened to support Alterity through its next stage of clinical development, partnering and comme

    1/30/26 7:25:00 AM ET
    $ATHE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Alterity Therapeutics Issues Shareholder Letter Highlighting 2025 Progress and Key Objectives for 2026

    MELBOURNE, Australia and SAN FRANCISCO, Jan. 21, 2026 (GLOBE NEWSWIRE) -- Alterity Therapeutics ((ASX: ATH, NASDAQ:ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today issued a letter to shareholders.  Dear Shareholders, Our goal for 2025 was the successful completion of the Phase 2 program investigating our lead asset, ATH434, in multiple system atrophy (MSA) and to produce data that would enable us to advance into Phase 3. We accomplished this mission and then some. Results from the Phase 2 trials were resoundingly favourable with data demonstrating the drug to be safe and well-tolerated

    1/21/26 7:25:00 AM ET
    $ATHE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ATHE
    $ATPC
    $BIVI
    $HSCS
    Financials

    Live finance-specific insights

    View All

    HeartSciences Provides Business Update and Reports First Quarter of Fiscal 2026 Financial Results

    Southlake, TX, Sept. 11, 2025 (GLOBE NEWSWIRE) -- HeartSciences Inc. (NASDAQ:HSCS, HSCSW)) ("HeartSciences" or the "Company"), an artificial intelligence ("AI")-powered medical technology company transforming ECGs/EKGs to enable earlier detection of heart disease, today announced its financial results for the first quarter of fiscal 2026 ended July 31, 2025 ("FQ1 2026") and provided a business update highlighting continued progress. First Quarter and Recent Highlights HeartSciences has made substantial progress during FQ1 2026 which saw the Company achieve an FDA Breakthrough Device Designation and successfully launched MyoVista Insights. MyoVista Insights™ Software Platform HeartScie

    9/11/25 4:15:00 PM ET
    $HSCS
    Industrial Specialties
    Health Care

    BioVie Highlighted ADDRESS-LC Phase 2 Trial Design Exploring Bezisterim for the Treatment of Neurological Symptoms of Long COVID at Keystone Symposia on Long COVID and Other Post-Acute Infection Syndromes

    CARSON CITY, Nev., Aug. 13, 2025 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ:BIVI) ("BioVie" or the "Company"), a clinical-stage company developing innovative drug therapies for neurological and neurodegenerative diseases, today announced that a poster highlighting the design and enrichment strategy of its ongoing Phase 2 ADDRESS-LC trial will be presented at the Keystone Symposia on Long COVID and Other Post-Acute Infection Syndromes, held August 10–13 in Santa Fe, New Mexico.   Long COVID is now recognized as a leading neurological condition that has affected an estimated 400 million individuals worldwide,1,2 .The Centers for Disease Control has reported that 6.9% of adults in the United St

    8/13/25 4:05:00 PM ET
    $BIVI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    HeartSciences Provides Business Update and Reports Fiscal 2025 Financial Results

    Southlake, TX, July 24, 2025 (GLOBE NEWSWIRE) -- HeartSciences Inc. (NASDAQ:HSCS, HSCSW)) ("HeartSciences" or the "Company"), an artificial intelligence ("AI")-powered medical technology company transforming ECGs/EKGs to enable earlier detection of heart disease, today announced its financial results for the fiscal year ended April 30, 2025, and provided a business update highlighting significant strategic progress. Fiscal 2025 and Business Highlights HeartSciences made substantial advancements during fiscal year 2025, marking a pivotal shift in its strategy to enhance the clinical value of ECGs through AI and cloud-based technologies that can be deployed across diverse healthcare settin

    7/24/25 4:15:00 PM ET
    $HSCS
    Industrial Specialties
    Health Care

    $ATHE
    $ATPC
    $BIVI
    $HSCS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Seelos Therapeutics Inc.

    SC 13G/A - SEELOS THERAPEUTICS, INC. (0001017491) (Subject)

    12/4/24 1:29:12 PM ET
    $SEEL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Seelos Therapeutics Inc.

    SC 13G/A - SEELOS THERAPEUTICS, INC. (0001017491) (Subject)

    11/14/24 7:32:44 PM ET
    $SEEL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by PaxMedica Inc.

    SC 13G/A - PaxMedica, Inc. (0001811623) (Subject)

    11/14/24 7:22:38 PM ET
    $PXMD
    Medicinal Chemicals and Botanical Products
    Health Care